RANZCP homepage
Date
24 October 2023
Profile
Dr Ken Gillman
Dr P Ken Gillman, MRCPsych, is Principal Researcher and Director at ‘PsychoTropical Research’ (PTR), Founder of the International MAOI Expert Group & Chairman of the Presiding Council. Dr Gillman is widely regarded as a leading authority on serotonin toxicity (ST), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and related topics.
Ken Gillman and his team at PTR continue to publish papers in the areas of his special expertise in the peer-reviewed scientific literature and on the psychotropical website for education of medical professionals and laypeople for 20 years.
Dr Gillman has an H-index of 29 and more than 4,700 citations and many major single-author review papers that have been extensively cited (between 100-700 times), focussing on TCAs, MAOIs, ST, and NMS. He has also published collaborative papers with a number of the most eminent names in psychopharmacology.
Dr P Ken Gillman, MRCPsych, is Principal Researcher and Director at ‘PsychoTropical Research’ (PTR), Founder of the International MAOI Expert Group & Chairman of the Presiding Council. Dr Gillman is widely regarded as a leading authority on serotonin toxicity (ST), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and related topics.
Ken Gillman and his team at PTR continue to publish papers in the areas of his special expertise in the peer-reviewed scientific literature and on the psychotropical website for education of medical professionals and laypeople for 20 years.
Dr Gillman has an H-index of 29 and more than 4,700 citations and many major single-author review papers that have been extensively cited (between 100-700 times), focussing on TCAs, MAOIs, ST, and NMS. He has also published collaborative papers with a number of the most eminent names in psychopharmacology.
Questions from the audience
- What advice do you give around MAOI interactions with food?
- Who has initiated using an MAOI and why? (Question directed to audience)
- Which type of agent do you use for which type of depression?
- The STAR*D trial had an arm with MAOIs, and they were found to not be of much benefit compared to the other strategies. Did that have to do with the way the study was put together?
- If you were heading up the NHMRC what trial would you sponsor?
- With MAOIs it’s ‘start low, go slow’. When it comes to ‘go slow’, how do you judge how quickly to increase the dose?
- How high (dosage) do you go?
- Working with older folk there is some trouble treating anxiety. Early dementia can have very hard to treat anxiety. How do you feel about using phenelzine versus benzodiazepines?
- The mood disorder guidelines from RANZCP talks about using MAOIs in the case of atypical symptoms of depression. What is your experience with that?
- What should we do with the DSM?
- Do you want to comment on the European approach on whether you can look at ways medications actually work rather than building a false construct and then subjecting them to trials?
Further reading
Disclaimer
This session is a Member benefit of the RANZCP and for educational purposes only. The information may represent views of the author and not necessarily the views of the College. Information is subject to change and the College does not warrant that the information is current at the time of viewing and accepts no liability for any loss or damage suffered by you or a patient directly or indirectly as a result of relying on information provided and should not be a substitute for individual clinical judgement. By accessing e-learning sessions you also agree to the RANZCP Website Terms of Use Agreement.
